Resources

1 Resources for

regulus

Subscribe to this listing via:
RSS
Email

BNET Resources

Glaxo to Buy Biotech Sirtris in $720 Mln Deal: By Ransdell Pierson NEW YORK (Reuters UK) - GlaxoSmithKline GSK said on Tuesday it had agreed to buy biotechnology company Sirtris Pharmaceuticals Inc SIRT for $720 million (360.69 million pounds) in cash, in hopes its medicines that modulate an aging-related family of enzymes will be...; Tags: Glaxo, Type 2, Regulus, Biotechnology, Alnylam Pharmaceuticals Inc., GlaxoSmithKline Plc., Isis Pharmaceuticals Inc., Sirtris Pharmaceuticals Inc.; News items 2008-04-22

Additional Resources

regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases: CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has obtained exclusive rights from Stanford University to worldwide patent applications covering methods...; Articles 2008-05-06
The stars in May: It's easy to see the universe in black and white. Glance up at the sky, and it looks as though the stars are white pinpricks on the black velvet background. But look more carefully, and you'll see that the brighter objects all have subtle hues of colour. ...; Articles 2008-04-30
GlaxoSmithKline and regulus Therapeutics Form Strategic Alliance To Develop MicroRNA Targeted Therapeutics to Treat Inflammatory Diseases: Companies Announce Significant microRNA Therapeutics Collaboration LONDON & PHILADELPHIA & CARLSBAD, Calif. -- GlaxoSmithKline GSK and Regulus Therapeutics LLC Regulus today announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Regulus is...; Articles 2008-04-17
regulus Therapeutics to Host Conference Call to Discuss GlaxoSmithKline Alliance: CARLSBAD, Calif. & CAMBRIDGE, Mass. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will hold a conference call this morning, Thursday, April 17, at 8:00 a.m. ET to discuss its new alliance with GlaxoSmithKline. ...; Articles 2008-04-17

March nights out: 5 Mercury, Venus, and a narrow sliver of a waning crescent Moon will rise about an hour before sunup to form a broad triangle about five degrees wide in the east-southeast. Your best bet is to use binoculars. Jupiter is easier to spot at this time, sitting high in the...; Articles 2008-03-01
regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer: CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA therapeutics, announced today the appointment of Peter S. Linsley, Ph.D., as Chief Scientific Officer. Dr. Linsley has been instrumental...; Articles 2008-02-11
Alnylam Pharmaceuticals Reports Fourth Quarter and 2007 Financial Results: - Completed 2007 with $455.6 Million in Cash and Achieved Over $50 Million in Revenues - - Advanced ALN-RSV01 Program through Phase II Development with Positive Results - - Forged Major Alliance with Roche and Formed Regulus Therapeutics Joint Venture - - Continued Scientific...; Articles 2008-02-07
regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer: CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop and commercialize microRNA therapeutics, announced today the appointment of Kleanthis G. Xanthopoulos, Ph.D., as President and Chief Executive Officer. Dr. Xanthopoulos is...; Articles 2007-12-03
regulus Therapeutics Announces Allowance of Key Patent on microRNA Therapeutics for the Treatment of Hepatitis C Virus Infection: New Patent Strengthens Regulus' Leadership in microRNA Therapeutics CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA therapeutics, announced today that the United States Patent and Trademark...; Articles 2007-11-19
The sky in November: Mercury becomes easy to see with the naked eye in the morning sky early this month; for northern observers, this apparition is its most favorable one of the year. The planet starts the month rising more than an hour before sunup, far below and to the left of Venus, and...; Articles 2007-11-01
regulus Expands Electronic Payment Offerings, Partners With ChoicePay to Give Customers Best-in-Class Capabilities: Regulus, the largest independent provider of paperand electronic bill presentment and remittance processingsolutions in the United States, today announced its partnership withe-payment services provider ChoicePay. With the addition of ChoicePay,Regulus is expanding its ePaymentssuite , a selection of e-payment, EBPP and related options that can berapidly deployed...; Articles 2007-10-17
Isis, Alnylam Pair To Seek Disease-Fighting Drugs: A promising new approach to targeting human diseases has generated interest from two rival companies accustomed to partnering for the good of science. On Sept. 7, Isis Pharmaceuticals Inc. and Alnylam Pharmaceuticals Inc. announced the formation of Regulus Therapeutics Inc., a biotechnology startup in Carlsbad focused on commercializing drugs...; Articles 2007-09-17
King works out Secret to crowning his big year: n equestrianism By Genevieve Murphyat Blenheim Chris King rode The Secret Weapon to claim his first three-day event victory yesterday at the Blenheim International Horse Trials, having completed a cool round under pressure to win the 5,000 first prize from Kristina Cook on Miners...; Articles 2007-09-10
King works out Secret to crowning his big year: n equestrianism By Genevieve Murphyat Blenheim Chris King rode The Secret Weapon to claim his first three-day event victory yesterday at the Blenheim International Horse Trials, having completed a cool round under pressure to win the 5,000 first prize from Kristina Cook on Miners...; Articles 2007-09-10
King works out Secret to crowning his big year: n equestrianism By Genevieve Murphyat Blenheim Chris King rode The Secret Weapon to claim his first three-day event victory yesterday at the Blenheim International Horse Trials, having completed a cool round under pressure to win the 5,000 first prize from Kristina Cook on Miners...; Articles 2007-09-10
BASEBALL [Derived headline]: BASEBALL American League: Detroit 3 Chicago White Sox 2; Baltimoree 6 Boston 7; LA Angels 10 Cleveland 3. National League: St Louis 16 Pittsburgh 4; Chicago Cubs 4 LA Dodgers 7. EQUESTRIANISM Blenheim International Horse Trials (Woodstock, Oxon): Standings after dressage:...; Articles 2007-09-08
Stockton puts herself in sight of dressage win: --equestrianism Polly Stockton, who wasrunner-up at Burghley on Sunday with Tom Quigley, showed continuing good form by holding the lead after yesterday's first day of dressage at the Blenheim International Horse Trials. This time she is riding Anne Henson's Regulus, who was also in the lead after the dressage phase...; Articles 2007-09-07
Stockton puts herself in sight of dressage win: --equestrianism Polly Stockton, who wasrunner-up at Burghley on Sunday with Tom Quigley, showed continuing good form by holding the lead after yesterday's first day of dressage at the Blenheim International Horse Trials. This time she is riding Anne Henson's Regulus, who was also in the lead after the dressage phase...; Articles 2007-09-07
Stockton puts herself in sight of dressage win: --equestrianism Polly Stockton, who wasrunner-up at Burghley on Sunday with Tom Quigley, showed continuing good form by holding the lead after yesterday's first day of dressage at the Blenheim International Horse Trials. This time she is riding Anne Henson's Regulus, who was also in the lead after the dressage phase...; Articles 2007-09-07

<< Previous
page 1 of 1
Next >>

Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors